Business Context and Reporting Period
This Form 8-K is filed by Cara Therapeutics, Inc. (the "Registrant") on April 11, 2025. The filing serves as a Regulation FD disclosure regarding a previously announced merger with Tvardi Therapeutics, Inc. ("Tvardi"). Tvardi is a clinical-stage biopharmaceutical company developing oral, small molecule therapies targeting STAT3 for fibrosis-driven diseases. Under the Merger Agreement dated December 17, 2024, Tvardi will merge with a Cara subsidiary and survive as a wholly-owned subsidiary of Cara.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity for either Cara Therapeutics or Tvardi Therapeutics. This report focuses on the disclosure of an investor presentation rather than financial performance data.
Material Changes
The primary material event is the furnishing of an investor presentation (Exhibit 99.1) related to the proposed Merger. This presentation is intended for potential investors in Tvardi and the post-combination company. No other material changes to operations or financial status are detailed in this specific text.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The filing contains statements regarding the anticipated completion of the Merger, the timeline for consummation, and the development progress of Tvardi's product candidates. Management cautions that actual results may differ materially from these expectations.
- Risks and Contingencies: Completion of the Merger is subject to the satisfaction or waiver of closing conditions. Risks include the uncertainty of the Merger's completion, potential termination of the Merger Agreement, and factors detailed in the "Risk Factors" section of the Form S-4 (File No. 333-283900) and Cara's Form 10-K.
- Legal Status: The information in this Item 7.01 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference into other filings except as expressly set forth.
- No Solicitation: This report does not constitute an offer to sell or a solicitation of an offer to buy securities.
Investor Verification Checklist
- Review the attached Investor Presentation (Exhibit 99.1) for specific details on the Merger terms and Tvardi's pipeline.
- Examine the Form S-4 (File No. 333-283900) for comprehensive risk factors and the full Merger Agreement details.
- Verify the status of closing conditions required to consummate the Merger.
- Check Cara Therapeutics' most recent Form 10-K for the company's current financial position and liquidity.